The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort
European Journal of Neurology · 2024
DOI: 10.1111/ene.16445 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Edgar Carnero Contentti und 16 weiteren Autor:innen. Beteiligte Einrichtung: Neuroimmunology Unit, Department of Neurosciences, Hospital Aleman, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein, Autoantibodies. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Purpose The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) were published in 2023. We aimed to determine the performance of the new criteria in Latin American (LATAM) patients compared with the 2018 criteria and explore the significance of MOG–IgG titers in diagnosis.
Methods
We retrospectively reviewed the medical records of LATAM (Argentina, Chile, Brazil, Peru, Ecuador, and Colombia) adult patients with one clinical MOGAD event and MOG‐IgG positivity confirmed by cell‐based assay. Both 2018 and 2023 MOGAD criteria were applied, calculating diagnostic performance indicators.
Results
Among 171 patients (predominantly females, mean age at first attack = 34.1 years, mean disease duration = 4.5 years), 98.2% patients met the 2018 criteria, and of those who did not fulfill diagnostic criteria ( n = 3), all tested positive for MOG‐IgG (one low‐positive and two without reported titer). Additionally, 144 (84.2%) patients met the 2023 criteria, of whom 57 (39.5%) had MOG‐IgG+ titer information (19 clearly positive and 38 low‐positive), whereas 87 (60.5%) patients had no MOG‐IgG titer. All 144 patients met diagnostic supporting criteria. The remaining 27 patients did not meet the 2023 MOGAD criteria due to low MOG‐IgG ( n = 12) or lack of titer antibody access ( n = 15), associated with the absence of supporting criteria. The 2023 MOGAD criteria showed a sensitivity of 86% (95% confidence interval = 0.80–0.91) and specificity of 100% compared to the 2018 criteria.
Conclusions
These findings support the diagnostic utility of the 2023 MOGAD criteria in an LATAM cohort in real‐world practice, despite limited access to MOG‐IgG titration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroimmunology Unit, Department of Neurosciences, Hospital Aleman, Buenos Aires, Argentina.
- Neurology Department, Dr. Ramón Carrillo Central Hospital, San Luis, Argentina.
- Neurology Department, Hospital Dr. Sótero del Río y Universidad Católica de Chile, Santiago, Chile.
- Basic Research Center in Dementia and Central Nervous System Demyelinating Diseases, Instituto Nacional de Ciencias Neurológicas, Lima, Peru.
- Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, São Paulo, Brazil.
- Neurology private practice, Pereira, Colombia.
ORCID-Profile: Edgar Carnero Contentti, Ethel Ciampi, Cesar Caparo Zamalloa, Berenice Silva
Zitieren
APA
Carnero Contentti, E., Pestchanker, C., Ciampi, E., Castro Suarez, S., Caparo Zamalloa, C., Daccach Marques, V., Messias, K., Gortari, J. I., Tkachuk, V., Silva, B., Mainella, C., Reyes, S., Toro, J., Rodriguez, J., Correa-Diaz, E., Rojas, J. I., & Paul, F. (2024). The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort. European Journal of Neurology. https://doi.org/10.1111/ene.16445
Vancouver
Carnero Contentti E, Pestchanker C, Ciampi E, Castro Suarez S, Caparo Zamalloa C, Daccach Marques V, et al. The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort. European Journal of Neurology. 2024. doi:10.1111/ene.16445
BibTeX
@article{CarneroContentti2024,
author = {Carnero Contentti, Edgar and Pestchanker, Claudia and Ciampi, Ethel and Castro Suarez, Sheila and Caparo Zamalloa, Cesar and Daccach Marques, Vanesa and Messias, Katharina and Gortari, José Ignacio and Tkachuk, Verónica and Silva, Berenice and Mainella, Carolina and Reyes, Saúl and Toro, Jaime and Rodriguez, Juan and Correa-Diaz, Edgar and Rojas, Juan I and Paul, Friedemann},
title = {The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16445}
}
EUVIMED